Clinical Research Directory

SPCG17: Prostate Cancer Active Surveillance Trigger Trial

Sponsor: Uppsala University

Summary

A large proportion of men with prostate cancer are overdiagnosed and overtreated mainly due to PSA testing. Active surveillance (AS) aims to reduce these harms by recommending curative treatment only when and if signs of tumor progression occur. There are however a number of uncertainties in AS, the most important being when to initiate treatment. The investigators are therefore starting a large randomized multicenter trial testing the safety of a standardized active surveillance protocol with specified triggers for repeat biopsies and initiation of curative treatment. The standardized protocol is compared with current practice for active surveillance. The primary aim of the study is to reduce overtreatment and subsequent side effects, without increasing the risk of disease progression or prostate cancer mortality.

Official title: SPCG17: Prostate Cancer Active Surveillance Trigger Trial (PCASTT)

Key Details

Conditions

Interventions

Locations (23)